No.45, Guangfu North Road
Hukou Township
Hsinchu City 303
Taiwan
886 3 597 9288
https://www.ubi-pharma.com
Settore/i: Healthcare
Settore: Drug Manufacturers—Specialty & Generic
Impiegati a tempo pieno:
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Chei-Hsiang Chen | Chairperson & Pres | N/D | N/D | N/D |
Meng Han Xu | Mang. of the Fin. Department | N/D | N/D | N/D |
Dr. Roger Kuo Ph.D. | Chief Operating Officer | N/D | N/D | N/D |
Jia Wei Hong | Mang. of Accounting Department | N/D | N/D | N/D |
Ms. Vivien Fan | Exec. VP, Spokesperson of the Admin. Center & Director | N/D | N/D | N/D |
Mr. Bai-Feng Wu | Sr. VP of Pharmaceutical Manufacturing | N/D | N/D | N/D |
Dr. Yan Ning Guo | COO of Pharmaceutical Bus. Center & Director | N/D | N/D | N/D |
Qi Hua Song | Head of the Quality Assurance & Norms Office and Deputy Plant Mang. | N/D | N/D | N/D |
Ming Yi Ba | Deputy Head of the Engineering Office | N/D | N/D | N/D |
UBI Pharma Inc. develops, manufactures, and sells pharmaceutical products in Taiwan. The company offers protein drugs and formulations of molecule products; and develops biobetters and specialty injectables. Its product portfolio includes film coated, Virapine, and Efanzy tablets, as well as Terbutaline; and Levetir concentrate solution for infusion. The company was founded in 2014 and is based in Hsinchu City, Taiwan.
L'ISS Governance QualityScore di UBI Pharma Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.